Sector Expert: Alan Carr

Needham & Co

Image: Alan Carr

Alan Carr joined Needham & Company in 2006. From 2001 to 2006 Alan worked in Yale’s technology transfer group, the Office of Cooperative Research, where he out-licensed a number of technologies and therapeutic product candidates developed in Yale labs and helped establish start-up companies in the New Haven area. Prior to that he was at J. Bush & Co., a New Haven investment firm, where he covered companies in the research tool and healthcare space. His post-doctoral work was centered on the regulation of neuronal development during embryogenesis. He earned his undergraduate degree at Albion College and earned his Ph.D. in Molecular Biophysics and Biochemistry from Yale University.



Recent Quotes

"MRK's Victrelis has substantially improved sustained virologic response rates."

The Life Sciences Report Interview with Alan Carr (6/7/12)
more >

"We saw some encouraging data from ADXN's metabotropic glutamate receptor 5 inhibitor."

The Life Sciences Report Interview with Alan Carr (6/7/12)
more >



Due to permission requirements, not all quotes are shown.